Evaluation of the clinical impact of different telemedicine practices in intensive care units: A stepped-wedge cluster randomized clinical trial (TELESCOPE 2): Study protocol Authors: Adriano José Pereira, Bruna Gomes Barbeiro, Tiago Mendonça dos Santos, Maura Cristina dos Santos, Thiago Domingos Corrêa, Alexandre Biasi Cavalcanti, Ary Serpa Neto, Carlos Henrique Sartorato Pedrotti, Fernando G Zampieri, Guilherme de Paula Pinto Schettino, Jorge Ibrain Figueira Salluh, Leandro Utino Taniguchi, Leonardo José Rolim Ferraz, Luciano Cesar Azevedo, Otávio Berwanger, Regis Goulart Rosa, Renata Albaladejo Morbeck, Rodrigo Biondi, Suzana Margareth Lobo, Renato Carneiro de Freitas Chaves, Otavio Ranzani Published: 2026 ABSTRACT AbstractBackgroundThe safety and feasibility of telemedicine in intensive care units (ICU) are well established. However, whether tele-ICU exerts a measurable impact on clinically relevant outcomes remains uncertain.ObjectiveTo evaluate whether a multifaceted Tele-ICU intervention, integrating intensivist-led daily multidisciplinary rounds (DMRs), coordinated care from a multidisciplinary team, and a quality and safety management strategy focused on quality improvement can reduce ICU length of stay among patients in Brazil.Design, setting, participants, and intervention: The TELESCOPE 2 study is a multicentre, open-label, stepped-wedge cluster randomized controlled trial including 25 ICUs in Brazil from January 2024 to January 2026. In a stepped-wedge assignment, ICUs will be randomized and allocated to one of five sequences. All ICUs will receive the interventions in a staggered manner at different times. All adult patients admitted in participant ICUs will be eligible for inclusion in the study. Admissions to the ICU due to justice-related issues (since in such circumstances the ICU admission or discharge may be determined by the law rather than by medical reasons), and patients previously included in the TELESCOPE 2 study will be excluded. The trial intervention is multifaceted, comprising three components delivered in combination, via telemedicine: I) daily multidisciplinary rounds led by board-certified intensive care physicians; II) coordinated care by a multidisciplinary team, including nurses, physiotherapists, and clinical pharmacists); III) a management strategy focused on quality improvement and patient safety.Main outcome measuresThe primary outcome is ICU length of stay. Secondary outcomes include ICU mortality, in-hospital mortality, ventilator-free days during the first 28 days, ICU readmission within 48 h, early reintubation, ventilator-associated events, and accidental extubation rate.ResultsThe TELESCOPE 2 study will assess whether a muiltifaceted Tele-ICU intervention can reduce ICU lenght of stay among critically ill patients in Brazil.ConclusionWe describe the study protocol for the TELESCOPE 2 trial, finalized prior to database lock. TELESCOPE 2 will evaluate the clinical impact of a structured Tele-ICU intervention in resource-variable ICUs and may provide robust evidence regarding the optimal model for delivering Tele-ICU.Keywords: Telemedicine, Critical care, Intensive care units, Quality improvement, Clinical outcomes Introduction Telemedicine in intensive care units (Tele-ICU) refers to a wide range of technology-enabled care delivered from remote locations.[1], [2], [3], [4], [5], [6] Tele-ICU integrates secure audio-visual connections and electronic medical records to facilitate remote collaboration between specialized intensive care professionals and on-site ICU staff.[1], [2], [3], [4], [5], [6] Additionally, tele-ICU has the appeal of offering a potential solution to the observed intensivist shortage and to the uneven distribution of specialized intensive care professionals in several countries across the globe.[1], [2], [3], [4], [5], [6] The adoption of tele-ICU has expanded rapidly and is increasingly promoted as a strategy to enhance the quality and consistency of care.[6], [7], [8] Tele-ICU enables remote daily multidisciplinary rounds (DMR) led by an intensive care specialist, provides tools for documenting these rounds, offers second opinions on clinical cases, facilitates consultations with other medical specialties, monitors vital signs in real-time, assists in patient management, and contributes to administrative workflows.9 Previous non-randomized studies have demonstrated that tele-ICU implementation is associated with reductions in ICU mortality,2,[6], [7], [8] hospital length of stay,[6], [7], [8] clinical complications,7 and faster response to alarms.8 Despite encouraging evidence from observational studies and systematic review with metanalysis,[1], [2], [3], [4], [5], [6], [7], [8] randomized clinical trials evaluating the impact of tele intensive care systems on patient-centred outcomes remain limited.9 The TELESCOPE trial, a parallel cluster randomized study conducted in 30 general units in Brazil and enrolling more than 17,000 patients, examined whether remote DMR combined with monthly audit and feedback sessions could reduce intensive care length of stay.9 Although the intervention was feasible and safe, it did not reduce the ICU length of stay among critically ill adult patients. Whether alternative tele-ICU models involving multidisciplinary teams, and management strategies carried out by specialized professionals, could improve outcomes remains unclear. The telescope 2 trial study aims to evaluate whether a multifaceted telemedicine intervention, comprising DMR led by board-certified intensive care physicians, coordinated care from a multidisciplinary team, and a management strategy focused on quality improvement and patient safety, can reduce the ICU length of stay for patients in Brazil. Methods Study design and setting The telescope 2 study is an open-label, national, multicentre, stepped-wedge cluster randomized controlled trial. This study protocol was designed according to the guidelines for Good Clinical Practice and the Declaration of Helsinki and is reported according to the SPIRIT statement.10 The study is registered at Clinicaltrials (www.clinicaltrials.gov; trial identification number NCT05960994), the Brazilian Registry of Clinical Trials (https://ensaiosclinicos.gov.br; trial identification number RBR-342wxn9), and the Universal Trial Number is U1111-1298-9799. The main characteristics of the Telescope 2 study are summarized in the Synopsis table (Table 1). Table 1Synopsis (ClinicalTrials.gov registration, as originally submitted).Table 1Data categoryInformationPrimary register and identification numberClinicalTrials.gov: NCT05960994Date of first registration17 July 2023Others identification numbers•PROADI: NUP 25000.153839/2021-11•Universal trial number: U1111-1298-9799•https://ensaiosclinicos.gov.br (ReBEC): RBR-342wxn9•Institutional review board approval: CAAE 69575123.0.1001.0071Development agency/funding sourceThe Brazilian Ministry of Health (Institutional for Development Support Program of the Unified Health System/SUS - Brazil)Primary sponsorThe Brazilian Ministry of HealthSecondary sponsorEinstein Hospital IsraelitaGeneral contactAJP, MD, PhD. Phone: +55 (11) 2151-1500E-mail: adriano.pereira2@einstein.brAcademic contactRCFC, MD, PhD, MBA. Phone: +55 (11) 2151-1500E-mail: renato.carneiro@einstein.brOfficial titleEvaluation of the clinical impact of different telemedicine practices in intensive care units: a stepped-wedge cluster randomized clinical trialBrief titleEvaluation of the clinical impact of different telemedicine practices in ICU (TELESCOPE 2)Countries involved in recruitmentBrazilHealth conditions/problems studiedTelemedicine, critical care, intensive care unitsInterventionsThree interventions, delivered in combination, via telemedicine:•Daily multidisciplinary rounds conducted by board-certified intensive care physicians.•Coordinated care by a multidisciplinary team, involving a team of nurses, physiotherapists, and clinical pharmacists.•Management strategy focused on quality improvement and patient safety, delivered by intensivists also qualified as management specialists, focused on quality improvement and patient safety.ControlAllocation is not parallel, so there is no fixed control group; however, all centers act as controls, because each sequence includes a different duration for the control period (without any intervention)Main inclusion criteria for intensive care units•ICUs from public or philanthropic hospitals•ICUs with physician and nurses available 24 h a day and physiotherapist available at least ≥18 h a dayMain exclusion criteria for ICU•ICUs with structured multidisciplinary rounds, defined as meetings (DMRs) ≥ 3 times per week, during weekdays, conducted by a board-certified intensivist and documented in medical records with fixed visit length (>5 min/patient), using some supporting tool (checklist or standard form), goal-oriented, based on established protocols, including all the patients admitted to the ICU•ICUs with implemented monthly management of indicators (audit and feedback) with specific planning•Dedicated coronary care units/cardiac intensive care units or other specialized units (e.g, neurological, burned patients)•Step-down or intermediate care units•ICUs without availability of renal replacement therapy•ICUs in which coordinators are board-certified intensivists, and qualified as Master of Business Administration (or an equivalent)Main inclusion criteria for patients•Adult patients (≥18 years old)•Sex: both•Accepts volunteers: noMain exclusion criteria for patients•Admission for other reasons than medical (e.g., judicial cause, legal reasons, safety reasons)•Previously included in the TELESCOPE 2 trial (for the primary outcome analysis)Type of study•Intervention/cluster•Allocation: randomization sequences stratified by region and length of stay•Intervention design: Stepped-wedge cluster randomized trial with 5 parallel sequences•Masking: Open•Primary purpose: Quality improvementExpected date of first inclusionJanuary 2024Sample size25 clusters, from 18,750 to 25,000 patientsRecruitment statusInitiated (expected for 2024)Primary outcomeLength of stay in the ICU, measured in hours (derived in 24 h periods with decimal places), defined as the time interval in hours between patients' ICU admission and the moment of ICU physical discharge or ICU deathSecondary outcomes•ICU mortality•In-hospital mortality•Ventilator-free days during the first 28 days•ICU readmission within 48 h•Early reintubation (<48 h after elective extubation)•Ventilator-associated events•Accidental extubation rateAbbreviations: ICU = intensive care unit. Synopsis (ClinicalTrials.gov registration, as originally submitted). •PROADI: NUP 25000.153839/2021-11 PROADI: NUP 25000.153839/2021-11 •Universal trial number: U1111-1298-9799 Universal trial number: U1111-1298-9799 •https://ensaiosclinicos.gov.br (ReBEC): RBR-342wxn9 https://ensaiosclinicos.gov.br (ReBEC): RBR-342wxn9 •Institutional review board approval: CAAE 69575123.0.1001.0071 Institutional review board approval: CAAE 69575123.0.1001.0071 Three interventions, delivered in combination, via telemedicine: Three interventions, delivered in combination, via telemedicine: •Daily multidisciplinary rounds conducted by board-certified intensive care physicians. Daily multidisciplinary rounds conducted by board-certified intensive care physicians. •Coordinated care by a multidisciplinary team, involving a team of nurses, physiotherapists, and clinical pharmacists. Coordinated care by a multidisciplinary team, involving a team of nurses, physiotherapists, and clinical pharmacists. •Management strategy focused on quality improvement and patient safety, delivered by intensivists also qualified as management specialists, focused on quality improvement and patient safety. Management strategy focused on quality improvement and patient safety, delivered by intensivists also qualified as management specialists, focused on quality improvement and patient safety. •ICUs from public or philanthropic hospitals ICUs from public or philanthropic hospitals •ICUs with physician and nurses available 24 h a day and physiotherapist available at least ≥18 h a day ICUs with physician and nurses available 24 h a day and physiotherapist available at least ≥18 h a day •ICUs with structured multidisciplinary rounds, defined as meetings (DMRs) ≥ 3 times per week, during weekdays, conducted by a board-certified intensivist and documented in medical records with fixed visit length (>5 min/patient), using some supporting tool (checklist or standard form), goal-oriented, based on established protocols, including all the patients admitted to the ICU ICUs with structured multidisciplinary rounds, defined as meetings (DMRs) ≥ 3 times per week, during weekdays, conducted by a board-certified intensivist and documented in medical records with fixed visit length (>5 min/patient), using some supporting tool (checklist or standard form), goal-oriented, based on established protocols, including all the patients admitted to the ICU •ICUs with implemented monthly management of indicators (audit and feedback) with specific planning ICUs with implemented monthly management of indicators (audit and feedback) with specific planning •Dedicated coronary care units/cardiac intensive care units or other specialized units (e.g, neurological, burned patients) Dedicated coronary care units/cardiac intensive care units or other specialized units (e.g, neurological, burned patients) •Step-down or intermediate care units Step-down or intermediate care units •ICUs without availability of renal replacement therapy ICUs without availability of renal replacement therapy •ICUs in which coordinators are board-certified intensivists, and qualified as Master of Business Administration (or an equivalent) ICUs in which coordinators are board-certified intensivists, and qualified as Master of Business Administration (or an equivalent) •Adult patients (≥18 years old) Adult patients (≥18 years old) •Sex: both Sex: both •Accepts volunteers: no Accepts volunteers: no •Admission for other reasons than medical (e.g., judicial cause, legal reasons, safety reasons) Admission for other reasons than medical (e.g., judicial cause, legal reasons, safety reasons) •Previously included in the TELESCOPE 2 trial (for the primary outcome analysis) Previously included in the TELESCOPE 2 trial (for the primary outcome analysis) •Intervention/cluster Intervention/cluster •Allocation: randomization sequences stratified by region and length of stay Allocation: randomization sequences stratified by region and length of stay •Intervention design: Stepped-wedge cluster randomized trial with 5 parallel sequences Intervention design: Stepped-wedge cluster randomized trial with 5 parallel sequences •Masking: Open Masking: Open •Primary purpose: Quality improvement Primary purpose: Quality improvement •ICU mortality ICU mortality •In-hospital mortality In-hospital mortality •Ventilator-free days during the first 28 days Ventilator-free days during the first 28 days •ICU readmission within 48 h ICU readmission within 48 h •Early reintubation (<48 h after elective extubation) Early reintubation (<48 h after elective extubation) •Ventilator-associated events Ventilator-associated events •Accidental extubation rate Accidental extubation rate Abbreviations: ICU = intensive care unit. Sites and recruitment Twenty-five ICUs in Brazil, part of the Brazilian public health system, were recruited for this study. The ICUs were selected from a list of all Brazilian ICUs, provided by the National Council of Municipal Health Secretaries, with support from the of the Brazilian Ministry of Health, to reflect the actual distribution of ICU beds across Brazil's geographic regions. Patient and public involvement Patients or the public were not involved in the study design. Eligibility criteria and inclusion/exclusion criteria ICUs selected for the study were invited via electronic communication to participate in an interview aimed at assessing their eligibility, using an electronic feasibility assessment questionnaire. All patients admitted to the included ICUs will be eligible for inclusion in the study. The inclusion and exclusion criteria for both ICUs and eligible patients are detailed below. Inclusion criteria for ICUs •ICU from public or philanthropic hospitals. ICU from public or philanthropic hospitals. •ICUs with a minimum of 7 and a maximum of 20 beds. ICUs with a minimum of 7 and a maximum of 20 beds. •ICU with on-site registered doctors and nurses available 24 h a day and physiotherapist available at least ≥18 h a day. ICU with on-site registered doctors and nurses available 24 h a day and physiotherapist available at least ≥18 h a day. Exclusion criteria for ICUs •ICUs with structured multidisciplinary rounds, defined as meetings (DMRs) ≥ 3 times per week, during weekdays, conducted by a board-certified intensivist and documented in medical records with fixed visit length (>5 min/patient), using a supporting tool (checklist or standard form), goal-oriented, based on established protocols, including all patients admitted to the ICU. ICUs with structured multidisciplinary rounds, defined as meetings (DMRs) ≥ 3 times per week, during weekdays, conducted by a board-certified intensivist and documented in medical records with fixed visit length (>5 min/patient), using a supporting tool (checklist or standard form), goal-oriented, based on established protocols, including all patients admitted to the ICU. •ICUs with implemented monthly management of indicators (audit and feedback) with specific planning. ICUs with implemented monthly management of indicators (audit and feedback) with specific planning. •Coronary/cardiac intensive care units or other specialized units (e.g, neurological, burned patients). Coronary/cardiac intensive care units or other specialized units (e.g, neurological, burned patients). •Step-down or intermediate care units. Step-down or intermediate care units. •ICUs without availability of renal replacement therapy. ICUs without availability of renal replacement therapy. •ICUs in which coordinators are board-certified intensivists and qualified as Master of Business Administration (or an equivalent). ICUs in which coordinators are board-certified intensivists and qualified as Master of Business Administration (or an equivalent). Inclusion criteria for patients •All consecutive patients admitted to the ICU, aged 18 years or older after the beginning of the trial. All consecutive patients admitted to the ICU, aged 18 years or older after the beginning of the trial. Exclusion criteria for patients •Admission to the ICU due to justice-related issues (since in such circumstances the ICU admission or discharge may be determined by the law rather than by medical reasons). Admission to the ICU due to justice-related issues (since in such circumstances the ICU admission or discharge may be determined by the law rather than by medical reasons). •Patients previously included in the Telescope 2 study will be excluded from the primary outcome analysis (ICU length of stay). However, subsequent ICU admissions will be retained for the assessment of ICU readmission outcomes. Patients previously included in the Telescope 2 study will be excluded from the primary outcome analysis (ICU length of stay). However, subsequent ICU admissions will be retained for the assessment of ICU readmission outcomes. Interventions The trial comprises three interventions, delivered in combination, via telemedicine: •DMRs conducted by board-certified intensive care physicians. DMRs conducted by board-certified intensive care physicians. •Coordinated care by a multidisciplinary team, involving a team of nurses, physiotherapists, and clinical pharmacists. Coordinated care by a multidisciplinary team, involving a team of nurses, physiotherapists, and clinical pharmacists. •A management strategy focused on quality improvement and patient safety, delivered by intensivists also qualified as management specialists, focused on quality improvement and patient safety. A management strategy focused on quality improvement and patient safety, delivered by intensivists also qualified as management specialists, focused on quality improvement and patient safety. DMRs conducted by board-certified intensive care physicians DMRs with an intensivist are discussions led by remote board-certified intensivists. These DMRs will occur from Monday through Friday at a predetermined time, either in the morning or afternoon, based on the ICU's preference, in centres equipped with an environmental microphone/high-fidelity sound system, webcam, and high-resolution camera with remote web control. During the intervention period, all patients admitted to the participating ICUs will be exposed to the multifaceted remote intervention. On weekends and national holidays, DMRs will not be conducted, but there will be in place an urgent communication channel with the attending clinician and data collection will proceed as usual, allowing patient follow-up. The urgent communication channel is also available during weekdays. DMR will be performed with the aim to establish diagnostic hypotheses, identify active problems, and develop a therapeutic plan until the next DMR. Remote intensivists will provide evidence-based recommendations tailored to the local structural context. Standardized electronic forms, filled by the tele-ICU physicians, will guide the discussions and support daily patient monitoring. Recommendations will be communicated synchronously through audiovisual telemedicine platforms and documented in structured electronic forms accessible to the local ICU team. Standardised forms used to support DMRs are provided in Additional file 1. Coordinated care by a multidisciplinary team Coordinated care provided by a multidisciplinary team will collaborate with the tele-ICU physician and the on-site team. The team will include board-certified intensive care nurses, board-certified intensive care respiratory and physical therapists, and clinical pharmacists, supporting the therapeutic plan, implementing preventive strategies, and promoting early recognition of clinical deterioration. Recommendations will be communicated synchronously during tele-rounds and documented in structured electronic forms accessible to the local ICU team (Additional file 1). The multidisciplinary intervention will encompass protocol-driven recommendations across the spectrum of critical care management, including, but not limited to, optimisation of mechanical ventilation settings, sedation management, ventilator weaning readiness, early mobilisation, delirium prevention, antimicrobial stewardship, nutritional support, glycaemic control, prevention of healthcare-associated infections, venous thromboembolism prophylaxis, and reduction of unnecessary device utilisation. Recommendations will be adapted according to local resource availability, including staffing patterns, diagnostic support, medications, equipment, and institutional protocols. For example, ventilatory management strategies may be individualized according to locally available therapeutic and monitoring resources. Management strategy focused on quality improvement and patient safety The management strategy focused on quality improvement and patient safety, were performed by intensivists with formal training in healthcare management. These activities will be conducted, daily, from Monday to Friday, excluding national holidays, at predetermined times, based on performance indicators consolidated in an electronic dashboard, built with the Shiny App and R software (R Foundation for Statistical Computing, Vienna, Austria). The Tele-ICU medical coordinators will remotely meet with the local hospital leadership to discuss strategies for improving patient outcomes, develop strategies to prevent patient deterioration, evaluate readmissions within 48 h, identify potentially avoidable bed days, and assess local practices related to the prevention and control of healthcare associated infections, including bloodstream infections, urinary tract infections with or without catheter use, tracheitis, pneumonia, and ventilator-associated pneumonia. This integrated management intervention aims to enhance healthcare value by ensuring quality, safety, and efficiency in patient care. This management intervention will involve structured meetings conducted at different frequencies according to the nature of the quality and safety indicators under evaluation. Daily meetings will focus on supporting the identification and management of critically ill patients classified as “watcher patients”, defined according to predefined severity criteria, including patients requiring high-dose vasoactive support, severe acute respiratory distress syndrome, or other high-risk clinical conditions associated with an increased risk of deterioration. Weekly meetings will involve local ICU leadership and administrative personnel to discuss operational and organizational issues identified during safety assessments that may affect ICU care processes and patient outcomes. Monthly meetings between tele-ICU coordinators and local hospital leadership will focus on broader quality improvement initiatives, including optimisation of patient flow, prevention of avoidable clinical deterioration, reduction of potentially avoidable ICU bed-days, reinforcement of infection prevention strategies, and review of organisational performance indicators. These meetings will also include evaluation of ICU mortality, ICU readmissions within 48 h, and healthcare-associated infections. All recommendations generated during management meetings will be communicated synchronously through remote conferencing platforms and documented in structured electronic forms accessible to local ICU teams. Structured online forms will additionally be used to identify critical resource limitations affecting ICU functioning, including shortages of personnel, medications, equipment, or diagnostic support. Outcomes Primary outcome The primary outcome of this trial at the patient level is ICU length of stay (LOS) defined as the time interval in hours between the patients' ICU admission and the moment of ICU physical discharge times (i.e., transfer to another care facility or another hospital) or ICU death, as defined by the hospital's system date and time. Date and time will be entered by the health care worker responsible for data collection. ICU LOS will be derived in 24-h periods with decimal place.11 To assess the robustness of the findings, prespecified sensitivity analyses for the primary outcome were described in the statistical analysis plan (SAP). These analyses include adjustment for relevant covariates and competing-risk approaches accounting for death as a competing event that may preclude ICU discharge. Secondary outcomes The secondary outcomes of this study include assessing the impact of interventions implemented through telemedicine compared with a control period on the following outcomes: •ICU mortality, defined as death from any cause during the index ICU admission. ICU mortality, defined as death from any cause during the index ICU admission. •In-hospital mortality, defined as death from any cause during the index hospital admission. In-hospital mortality, defined as death from any cause during the index hospital admission. •Ventilator-free days during the first 28 days, defined as the number of days alive and free from mechanical ventilation for at least 24 consecutive hours. Patients who died before weaning were deemed to have zero ventilator-free days, and patients discharged from the hospital before 28 days were considered alive and free from mechanical ventilation at 28 days. Ventilator-free days during the first 28 days, defined as the number of days alive and free from mechanical ventilation for at least 24 consecutive hours. Patients who died before weaning were deemed to have zero ventilator-free days, and patients discharged from the hospital before 28 days were considered alive and free from mechanical ventilation at 28 days. •ICU readmission within 48 h.12 ICU readmission within 48 h.12 •Early reintubation (<48 h after elective extubation). Early reintubation (<48 h after elective extubation). •Ventilator-associated events, defined as either an increase in the daily minimum positive end-expiratory pressure (PEEP) of ≥3 cmH2O sustained for at least two consecutive calendar days following a period of at least two days of stable or decreasing PEEP, or an increase in the fraction of inspired oxygen (FiO2) by ≥ 20 percentage points sustained for at least two consecutive days after a minimum of two days of stable or decreasing FiO2 levels.13 Ventilator-associated events, defined as either an increase in the daily minimum positive end-expiratory pressure (PEEP) of ≥3 cmH2O sustained for at least two consecutive calendar days following a period of at least two days of stable or decreasing PEEP, or an increase in the fraction of inspired oxygen (FiO2) by ≥ 20 percentage points sustained for at least two consecutive days after a minimum of two days of stable or decreasing FiO2 levels.13 •Accidental extubation rate. Accidental extubation rate. Process-of-care and quality indicators •Patient mobilization density in the ICU, defined as the number of days the patient has undergone any form of mobilization, including passive movement of upper or lower limbs in bed, sitting on the edge of the bed or in a chair, or walking.14 Patient mobilization density in the ICU, defined as the number of days the patient has undergone any form of mobilization, including passive movement of upper or lower limbs in bed, sitting on the edge of the bed or in a chair, or walking.14 •Adherence to maintaining the head-of-bed elevation (30°–45°). Adherence to maintaining the head-of-bed elevation (30°–45°). •Adequate prevention of venous thromboembolism.15 Adequate prevention of venous thromboembolism.15 •Rate of patient-days under adequate sedation [defined by Richmond agitation and sedation scale (RASS) = −3 to +1].16 Rate of patient-days under adequate sedation [defined by Richmond agitation and sedation scale (RASS) = −3 to +1].16 •Rate of patient-days with oral or enteral nutrition. Rate of patient-days with oral or enteral nutrition. •Rate of patients with adequate glycemic control (defined as blood glucose = 70–180 mg/dL).9,15 Rate of patients with adequate glycemic control (defined as blood glucose = 70–180 mg/dL).9,15 •Rate of patient-days within normoxemia (defined as peripheral oxygen saturation = 92–96%).9 Rate of patient-days within normoxemia (defined as peripheral oxygen saturation = 92–96%).9 •Rate of central venous catheter use. Rate of central venous catheter use. •Central venous catheter dwell time. Central venous catheter dwell time. •Rate of indwelling urinary catheter use. Rate of indwelling urinary catheter use. •Indwelling urinary catheter dwell time. Indwelling urinary catheter dwell time. Unit-level organizational outcomes •Classification of the unit according to the profiles defined by standard resource use (SRU) and standardized mortality rate (SMR).17 SRU reflects the observed-to-expected rate of resource utilization, estimated as ICU LOS for surviving patients and adjusted for the patient's severity of illness. SMR reflects the observed/expected rate, according to acute physiology score (SAPS 3) of hospital deaths.17 The profiles are a combination of SMR (above or below the median) and SRU (above or below the median): Each unit can be assigned to one of four groups: ‘most efficient’ (SMR and SRU < median); ‘least efficient’ (SMR, SRU > median); ‘overachieving’ (low SMR, high SRU), and ‘underachieving’ (high SMR, low SRU).17 Classification of the unit according to the profiles defined by standard resource use (SRU) and standardized mortality rate (SMR).17 SRU reflects the observed-to-expected rate of resource utilization, estimated as ICU LOS for surviving patients and adjusted for the patient's severity of illness. SMR reflects the observed/expected rate, according to acute physiology score (SAPS 3) of hospital deaths.17 The profiles are a combination of SMR (above or below the median) and SRU (above or below the median): Each unit can be assigned to one of four groups: ‘most efficient’ (SMR and SRU < median); ‘least efficient’ (SMR, SRU > median); ‘overachieving’ (low SMR, high SRU), and ‘underachieving’ (high SMR, low SRU).17 The follow-up period to define all outcomes will be truncated at 90 days while in the hospital from ICU admission. Participant timeline and follow-up Eligible ICUs will be randomized and allocated to one of five sequences (Fig. 1). Each sequence will include at least a 3-month control period, followed by a 3-month transition period, and at least a 3-month intervention period. The duration of intervention varies by sequence, ranging from 19 months in sequence one to 3 months in sequence five. The total study duration is 25 months. As a stepped-wedge, all ICUs will receive all interventions, but at different times. Patients will be followed up until hospital discharge. Schematic diagram illustrating the trial timeline, control period, randomization, transition period, intervention period, and follow-up. Aiming maximum engagement, the study's executive committee will hold in-person meetings with all centres before the study intervention. Those meetings will occur within 30 days of the centre's transition date, with the goal of reviewing the study's key aspects and aligning on the proposed interventions. Additionally, aiming to maximize local teams' engagement, remote tele-ICU professionals will always start intervention, primary in loco, transitioning to telemedicine afterwards. Calculation of sample size and recruitment A detailed description of the sample size calculation will be provided in the SAP. In brief, a total sample size of 18,750 to 25,000 patients will be required to detect a 1.1-day reduction in ICU length of stay compared to baseline, attributed to the intervention package, with a significance level of 5% and a minimum power of 95%. This variation in total sample size is due to different estimates of patients per period in the 25 Brazilian ICUs in question. It is estimated that there will be a variation of 30–40 patients recruited per month per ICU. The sample size was estimated based on simulations of a mixed-effects model for ICU length of stay, using 1000 replications for each scenario and the Kenward-Roger correction. The natural logarithm of ICU length of stay was used as the outcome to account for its right-skewed distribution.18 Fixed effects included the intercept (2.079), a secular time trend of −0.012, corresponding to a monthly decrease of 0.012 units in log-transformed ICU length of stay, and an intervention effect of −0.148. This intervention effect corresponds to a 13.75% relative reduction from a baseline mean ICU length of stay of 8 days, equivalent to an absolute reduction of 1.1 days. Random effects included cluster-level variability, assumed to follow a normal distribution with variance 0.102; period-within-cluster variability, with variance of 0.019; and individual-level residual error, with variance 1.090. These assumptions correspond to an estimated intracluster correlation coefficient of 0.10 and a cluster autocorrelation coefficient of 0.84. These empirical estimates were derived using data from the TELESCOPE 1 trial.9 Sequence generation, allocation and implementation The 25 ICUs will be randomized into one of five sequences (Fig. 1). The allocation sequence will be computer-generated by a statistician (TMS) and a clinical trialist from the study's executive committee (OTR) using random numbers, stratified by region (south/southeast, and central-west/north/northeast) and baseline length of stay, estimated from the first two months of the study within the initial period. Length of stay will be categorized into two strata: below the regional median and above the regional median. All ICUs will be randomized simultaneously, with the ICU serving as the unit of randomization, since the intervention is applied to the entire multidisciplinary team. To ensure allocation concealment, only the statistician responsible for the randomization list will know the sequence and will reveal the next sequence 30 days before the start of the transition. This period is necessary to organize the in-person meeting with the centre. The allocation concealment will be maintained until the end of the study. Blinding (masking) The intervention is open, due to the nature of the study, i.e., DMRs, quality improvement meetings and the delivery of evidence-based clinical protocols. The statisticians and research team will be blinded for analysis, and discussion. Data collection Forms detailing data collection during DMRs conducted by the physicians, nurses, physiotherapists, and clinical pharmacists are included in the Additional file 1. At the patient level, frequency of data collection is outlined in Table 2, and the following data will be collected: Table 2Patient data collection schedule.Table 2Baseline periodAfter randomizationAdmissionDailyDischargeAdmissionDailyDischargePatient detailsxxPre ICU eventsxxType and cause of admissionxxSeverity scores (SAPS 3 and SOFA)xxComorbidities/functional statusxxOrgan support and devicesxxxxTreatment goalsxxHospital-acquired infectionsxxLength of stay (ICU/hospital)xxxxMortality and destination (ICU/hospital)xxxxAbbreviations: ICU = intensive care unit. SAPS = Simplified Acute Physiology; SOFA = Sequential Organ Failure Assessment. Patient data collection schedule. Abbreviations: ICU = intensive care unit. SAPS = Simplified Acute Physiology; SOFA = Sequential Organ Failure Assessment. At the time of ICU admission •Identifier, date of birth, sex, race, main reason for ICU admission (adapted from Acute Physiology and Chronic Health Disease Classification System-APACHE III),19 readmission status. Identifier, date of birth, sex, race, main reason for ICU admission (adapted from Acute Physiology and Chronic Health Disease Classification System-APACHE III),19 readmission status. •Anthropometric characteristics, comorbidities (adapted from SAPS 3),20 functional status before hospitalization. Anthropometric characteristics, comorbidities (adapted from SAPS 3),20 functional status before hospitalization. •Respiratory, cardiovascular and renal support.9,21,22 Respiratory, cardiovascular and renal support.9,21,22 •Diet, sedation status, and vasoactive drugs.9 Diet, sedation status, and vasoactive drugs.9 •Presence of devices: central venous catheter (CVC), arterial line, permanent catheters, urinary catheter, oro/nasotracheal catheter and tracheostomy. Presence of devices: central venous catheter (CVC), arterial line, permanent catheters, urinary catheter, oro/nasotracheal catheter and tracheostomy. •Date and time of hospital admission. Date and time of hospital admission. •Date and time of ICU admission. Date and time of ICU admission. •SAPS 3 score.20 SAPS 3 score.20 •Sequential organ failure assessment (SOFA) score.23 Sequential organ failure assessment (SOFA) score.23 Throughout the ICU admission •Documented goals from the DMR (additional file 1). Documented goals from the DMR (additional file 1). •Documented discharge order status, defined as any mention of readiness for discharge or an ICU transference order. Documented discharge order status, defined as any mention of readiness for discharge or an ICU transference order. •Mechanical ventilation (MV) status and MV parameters. Mechanical ventilation (MV) status and MV parameters. •Peripheral saturation of haemoglobin measured by pulse oximetry range for patients on oxygen therapy. Peripheral saturation of haemoglobin measured by pulse oximetry range for patients on oxygen therapy. •Head-of-bed elevation for patients under MV. Head-of-bed elevation for patients under MV. •Spontaneous respiratory test, accidental extubation or reintubation events. Spontaneous respiratory test, accidental extubation or reintubation events. •Need of vasoactive drugs and renal replacement therapy. Need of vasoactive drugs and renal replacement therapy. •Continuous sedative infusion and light sedation strategy (reduction/daily interruption). Continuous sedative infusion and light sedation strategy (reduction/daily interruption). •Daily value (categorized as below, above or within −3 to +1 range) of the RASS for patients undergoing continuous sedation at a predetermined time.16 Daily value (categorized as below, above or within −3 to +1 range) of the RASS for patients undergoing continuous sedation at a predetermined time.16 •Glasgow coma scale. Glasgow coma scale. •Adequacy of venous thromboembolism prophylaxis [considered adequate when patient is bedridden without any of the following exclusion criteria: active bleeding, stress gastric ulcer, uncontrolled arterial hypertension (>180/110 mm Hg), coagulation disorder, allergy, kidney failure (Cl < 30 mL/min), ocular or cranial surgery in last 2 weeks, and lumbar puncture in the last 24 h)]. Adequacy of venous thromboembolism prophylaxis [considered adequate when patient is bedridden without any of the following exclusion criteria: active bleeding, stress gastric ulcer, uncontrolled arterial hypertension (>180/110 mm Hg), coagulation disorder, allergy, kidney failure (Cl < 30 mL/min), ocular or cranial surgery in last 2 weeks, and lumbar puncture in the last 24 h)]. •Presence of oral or enteral nutrition. Presence of oral or enteral nutrition. •Glycaemic control: considered adequate if between 70 and 180 mg/dL.9 Glycaemic control: considered adequate if between 70 and 180 mg/dL.9 •Notification of healthcare-related infection episodes according to Centers for Disease Control and Prevention (CDC) criteria:oCentral line-associated bloodstream infection.24oCatheter-associated urinary tract infection.25 Notification of healthcare-related infection episodes according to Centers for Disease Control and Prevention (CDC) criteria:oCentral line-associated bloodstream infection.24oCatheter-associated urinary tract infection.25 oCentral line-associated bloodstream infection.24 Central line-associated bloodstream infection.24 oCatheter-associated urinary tract infection.25 Catheter-associated urinary tract infection.25 •Mobilization activity. Mobilization activity. •Date and time of CVC insertion for patients undergoing CVC insertion. Date and time of CVC insertion for patients undergoing CVC insertion. •Date and time of withdrawal of CVC for patients undergoing CVC insertion. Date and time of withdrawal of CVC for patients undergoing CVC insertion. •Date and time of indwelling urinary catheter (IUC) insertion for patients submitted to IUC insertion. Date and time of indwelling urinary catheter (IUC) insertion for patients submitted to IUC insertion. •Date and time of withdrawal of IUC for patients undergoing IUC insertion. Date and time of withdrawal of IUC for patients undergoing IUC insertion. •Documentation of decisions for limiting the life support considering any mention to withholding or withdrawing in the medical records. Documentation of decisions for limiting the life support considering any mention to withholding or withdrawing in the medical records. At the time of ICU discharge •Date and time of ICU discharge. Date and time of ICU discharge. •ICU outcome: discharge to ward, hospital transfer, death. ICU outcome: discharge to ward, hospital transfer, death. At the time of hospital discharge •Date and time of hospital discharge. Date and time of hospital discharge. •Hospital outcome: hospital transfer, death. Hospital outcome: hospital transfer, death. Data management Trained healthcare workers will collect data, without any involvement from the study committees and investigators. A standard case report form was developed for the trial (additional file 2), with extensive validation and piloting aiming for clarity and consistency. Data will be entered using an electronic case report form in the Research Electronic Data Capture (REDCap®, USA) platform via internet, hosted on a server at the Einstein Hospital Israelita/São Paulo-Brazil.26,27 The system has different functionalities, including patient registration, data entry, data validation, data reports, data quality, data resolution workflow, audit trail, and data export for statistical analysis.26,27 Local investigators directly input data into the system, with comprehensive usage instructions always available to investigators. Electronic files will be securely stored at Einstein Hospital Israelita servers, in a controlled and confidential environment, with restricted access, following best practices. Regular remote data monitoring will promptly identify irregular patterns, inconsistencies, credibility concerns, or anomalies using predefined queries within the system. Missing or outlier data values will be individually reviewed, and follow-up reports are regularly reviewed by the coordinating centre to ensure consistency and completeness. Continuous efforts will be made to complete or rectify data whenever possible. Database cleaning and locking The database will be locked once all data have been entered and all discrepancies or missing data have been addressed. After this review, the database will be locked and prepared for statistical analysis. At this stage, access permissions for all investigators will be revoked, and the database will be archived. Statistical methods All analyses will be thoroughly described in the SAP, which will be concluded and submitted for publication elsewhere before the database is closed and analyses begin. Briefly, primary statistical analyses will be performed according to the intention-to-treat principle. All outcomes at the patient-level will be performed using models that account for correlated data within each ICU (i.e., ICU as a cluster) with generalized linear mixed models and adjusted by pre-specified covariates, as they will be specified in the SAP. Four subgroups were prespecified for analysis: type of admission (medical vs surgical), telemedicine experience (centres with vs. without prior telemedicine use), SAPS3 score (categorized by tertiles), mechanical ventilation status at admission (invasive vs. non-invasive x none), and ICU performance at baseline (four categories: most efficient, least efficient, overachieving, underachieving. Each classification will be made based on the first two months of the initial baseline period).9,28 Multiple imputation will be performed if missing data on core variables exceed 10%, following standard procedures for multiple imputation using chained equations with mice package. All analyses will be performed using R software R (V.4.2.0, the version will be updated at the time of analysis). Auditing The TELESCOPE 2 study is subject to audit by the Einstein Research Integrity Committee at any time, independently of the institutional review board, and the research team, following standard procedures. Ethical considerations The study will be performed according to national and international guidelines, adhering to the principles of the Declaration of Helsinki and the Act for Medical Research Involving Humans. The study was approved by the local Research Ethics Committee of the coordinating study centre (Einstein Hospital Israelita, CAAE: 69575123.0.1001.0071), as well as by local IRBs from each of the 25 participant centres, in compliance with Brazilian legislation. A specialist in regulatory processes will oversee and support the local teams. Any modifications to the protocol that may affect the study's development, potential benefits, or safety – including changes in the objectives, design, study population, sample size, interventions or relevant management aspects – require protocol amendments. These amendments should be submitted for approval to the IRB of the coordinating centre and all the IRBs at participating centres. Trial status This manuscript describes the protocol for the TELESCOPE 2 trial (original version 1, approved on June 28, 2023). The baseline period started on January 8, 2024, followed by randomization on March 8, 2024. The first transition period started on April 8, 2024, with the first interventions starting on July 8, 2024. At the time of the manuscript's submission, data collection for the trial was ongoing and is expected to be completed by January 31, 2026. Safety and monitoring Adverse events and interim analyses Considering that the study intervention incorporates the best available evidence for the care of critically ill patients in ICUs, interventions will be decided by consensus, and always validated by in loco professionals, and no major inherent risks are anticipated in the trial's execution, interim analyses are not planned. As a result, the constitution of a formal data monitoring committee was deemed unnecessary. While adverse events are not expected, they will be requested to be reported by local researchers, data assistants, and attending physicians. Patient information and informed consent The need for patients’ written informed consent was waived in all 25 centres.[29], [30], [31], [32], [33] Consent was obtained at the cluster level, with the hospital director and the head of the ICU (physician) responsible for signing the consent form in some cases, when requested by local IRBs.[29], [30], [31], [32], [33] This approach was approved by all the local IRBs (including the coordinating centre and the IRBs of the 25 participating ICUs). Data confidentiality Patients and the participating centres will be identified by corresponding numbers in the electronic data collection form to maintain anonymity. Data obtained from medical records will be handled confidentially and stored keeping restricted access, only authorized to part of the research team (directly linked to data collection and data management). Anonymization of all data, both in provisional and final reports, will be ensured, with no identifiable information disclosed. Research sites must securely store all data for the duration specified by the study and in accordance with local regulations. After this period, data must be securely incinerated (if physical) and/or excluded (if digital) to prevent unauthorized access. Research team is committed to taking all necessary precautions to guarantee data confidentiality throughout the study and beyond. Publication and administrative aspects Coordinating centre The coordinating centre for the study is Einstein Hospital Israelita in São Paulo, Brazil. Its responsibilities include planning and overseeing the study, preparing the study protocol and data collection forms, developing the operations manual, managing and ensuring data quality, conducting statistical analyses, and preparing the final manuscript. Public disclosure and publication policy The Telescope 2 group will publish the study findings regardless of the results. The main manuscript will be submitted by the executive and writing committee on behalf of the Telescope 2 research group. Organization Local Principal Investigators (PIs) will be responsible for site recruitment and overseeing the proper execution of the study. PIs at each participating centre will provide both scientific and structural leadership, ensuring that all required local ethical and regulatory approvals are obtained before patient enrolment. They will also train and supervise local data assistants, ensuring the accuracy of data collection and proper entry of data into the electronic medical record. The Steering Committee (composed by invited and highly experienced Brazilian researchers in the critical care field) provides high-level, independent oversight, ensuring patient safety, scientific integrity, and adherence to protocols, while the Executive Committee (EC)/Trial Management Group makes critical, executive decisions on the study's direction, resource allocation, and routine problem-solving. Funding The Brazilian Ministry of Health (Institutional Development Program of the Unified Health System-PROADI SUS) was the primary source of funding, including costs for physician services, the purchase of equipment (hardware) for telemedicine sessions, the hiring of local professionals for data collection and travel expenses for training and monitoring. The same funding also covered costs related to the regulatory part of the study-data collection, monitoring, data curation and statistical support. The Einstein Hospital Israelita allocated the time of professionals and specialists who sat on the executive and steering committees of the study, as well as assign its telemedicine service system. CRediT authorship contribution statement Executive and steering committee (RCFC, BGB, MCS, TMS, TDC, OTR, AJP) - conceptualisation, writing (original draft), writing (review and editing), methodology, and formal analysis. Advisory and scientific committe (ABC, ASN, CHSP, FGZ, GPPS, JIFS, LUT, LJRF, LCA, OB, RGS, RAM, RB, SML) - writing (review and editing), and methodology. Conflict of interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Ary Serpa Neto declares they are part of the CC&R editorial team as the co-Editor in Chief. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Acknowledgements The authors would like to thank the central TELESCOPE 2 team, data collection team of each participating ICU, as well as the Einstein Hospital Israelita, and the Brazilian Ministry of Health. Footnotes Supplementary data to this article can be found online at https://doi.org/10.1016/j.ccrj.2026.100193. Collaborators Coordinating Centre: Einstein Hospital Israelita Executive and steering committee: Renato Carneiro de Freitas Chaves, Bruna Gomes Barbeiro, Maura Cristina dos Santos, Tiago Mendonça dos Santos, Thiago Domingos Corrêa, Otavio T. Ranzani, Adriano José Pereira. Advisory and scientific committee: Alexandre Biasi Cavalcanti, Ary Serpa Neto, Carlos Henrique Sartorato Pedrotti, Fernando Zampieri, Guilherme de Paula Pinto Schettino, Jorge Ibrain Figueira Salluh, Leandro Utino Taniguchi, Leonardo José Rolim Ferraz, Luciano Cesar Azevedo, Otávio Berwanger, Regis Goulart Rosa, Renata Albaladejo Morbeck, Rodrigo Biondi, Suzana Margareth Lobo. Experts Committee (multidisciplinar team): Alessandra Gomes Chauvin, Aline Cristina Pedroso, Barbara Barduchi, Beatriz Rocha Monteiro, Camila de Carvalho Gambin, Cilene Saghabi, Eliton Paulo Leite Lourenço, Erika Yumiko Kumoto, Fabiana Rossi Varallo, Fernanda Paulino Fernandes, Flavia Oliveira Rodrigues, Flavia Veronezi Stankevicius, Gabrielli Pare Guglielmi, Gean Carlos Alves Moraes, Giovana Roberta Zelezoglo, Lidiane Soares Sodre da Costa, Luciana Laversveiler Moraes da Costa, Jessica Tamiris Romano, Joao Paulo Victorino, Marcele Pessavento, Raquel Afonso Caserta Eid, Renata de Souza Cyrino, Roberta Gonsalez dos Santos, Silvana Maria de Almeida, Tatiana Aporta Marins. Experts Committee (management team): Amanda Valle, Ana Cláudia Ferraz, Ana Lúcia Martins da Silva, Bruno de Arruda Bravim, Bruno Mazza, Daiane Seger, Felipe Maia de Toledo Piza, Gilberto Friedman, Glauco Whestphal, Guilherme de Paula Pinto Schettino, Gustavo Faissol Janot de Matos, Haggéas da Silveira Fernandes, Hipólito Carraro Jr., Joan Castro, Juliana Anacleto, Marcele Pesavento, Murillo Santucci Cesar de Assunção, Nelson Akamine, Niklas Soderberg Campos, Walace de Souza Pimentel. Research back office: Ana Cristina Lagoeiro Patrocinio da Cruz, Andrea Moreira de Freitas, Lucelio De Sousa Rocha, Lenine Melo Lino, Rodrigo Flor de Moura. LIST OF HOSPITALS PARTICIPATING IN THE STUDY AND LOCAL PRINCIPAL INVESTIGATORS (LPI). -Hospital Ana Nery, Salvador, BA. LPI: Luiz Carlos Santana Passos. Hospital Ana Nery, Salvador, BA. LPI: Luiz Carlos Santana Passos. -Hospital das Clínicas Luzia de Pinho Melo, Mogi das Cruzes, SP. LPI: Daniella de Rezende Duarte Maksymczuk. Hospital das Clínicas Luzia de Pinho Melo, Mogi das Cruzes, SP. LPI: Daniella de Rezende Duarte Maksymczuk. -Hospital de Emergência Dr. Daniel Houly, Arapiraca, AL. LPI: Guacyra Almeida. Hospital de Emergência Dr. Daniel Houly, Arapiraca, AL. LPI: Guacyra Almeida. -Hospital de Emergência e Trauma Dom Luiz Gonzaga Fernandes, Campina Grande, PB. LPI: Dagjane Martins Frazão Hospital de Emergência e Trauma Dom Luiz Gonzaga Fernandes, Campina Grande, PB. LPI: Dagjane Martins Frazão -Hospital Dr. Genesio Rego, São Luís, MA. LPI: Thamyris Danusa da Silva Lucena. Hospital Dr. Genesio Rego, São Luís, MA. LPI: Thamyris Danusa da Silva Lucena. -Hospital Dr. Leo Orsi Bernardes, Itapetininga, SP. LPI: Vivian Menezes Irineu. Hospital Dr. Leo Orsi Bernardes, Itapetininga, SP. LPI: Vivian Menezes Irineu. -Hospital Mangabeira Governador Tarcísio Burity, João Pessoa, PB. LPI: Madson Mariz Melo Tavares. Hospital Mangabeira Governador Tarcísio Burity, João Pessoa, PB. LPI: Madson Mariz Melo Tavares. -Hospital Estadual de Doenças Tropicais Dr. Anuar Auad, Goiânia, GO. LPI: Adriana Rocha de Carvalho Sousa. Hospital Estadual de Doenças Tropicais Dr. Anuar Auad, Goiânia, GO. LPI: Adriana Rocha de Carvalho Sousa. -Hospital Estadual de Luziânia, Luziânia, GO. LPI: Renata Meireles Roriz de Moraes, Patricia Alves de Castro Porto Marinho. Hospital Estadual de Luziânia, Luziânia, GO. LPI: Renata Meireles Roriz de Moraes, Patricia Alves de Castro Porto Marinho. -Hospital Geral de Roraima, Boa Vista, RR. LPI: Mauro Shosuka Asato, Hospital Geral de Roraima, Boa Vista, RR. LPI: Mauro Shosuka Asato, -Hospital Maternidade e Pronto Socorro Santa Lúcia, Poços de Caldas, MG. LPI: Ricardo Reinaldo Bergo. Hospital Maternidade e Pronto Socorro Santa Lúcia, Poços de Caldas, MG. LPI: Ricardo Reinaldo Bergo. -Hospital Municipal de Santarém, Santarém, PA. LPI: Antonio Carlos Alves da Silva. Hospital Municipal de Santarém, Santarém, PA. LPI: Antonio Carlos Alves da Silva. -Hospital Municipal Padre Germano Lauck, Foz do Iguaçu, PR. LPI: Roberto de Almeida. Hospital Municipal Padre Germano Lauck, Foz do Iguaçu, PR. LPI: Roberto de Almeida. -Hospital Municipal Salgado Filho, Rio de Janeiro, RJ. LPI: Claudia Valeria Pereira de Oliveira. Hospital Municipal Salgado Filho, Rio de Janeiro, RJ. LPI: Claudia Valeria Pereira de Oliveira. -Hospital Municipal Senhora Santana, Brasília de Minas, MG. LPI: Breno Mendes Cardoso. Hospital Municipal Senhora Santana, Brasília de Minas, MG. LPI: Breno Mendes Cardoso. -Hospital Nossa Senhora das Dores, Itabira, MG. LPI: Thállassa Fürst Guerra Procópio, Edilene Aparecida dos Santos. Hospital Nossa Senhora das Dores, Itabira, MG. LPI: Thállassa Fürst Guerra Procópio, Edilene Aparecida dos Santos. -Hospital Padre Máximo, Venda Nova do Imigrante, ES. LPI: Monica Paula de Deus Cezati, Maria Caroline de Souza Marques. Hospital Padre Máximo, Venda Nova do Imigrante, ES. LPI: Monica Paula de Deus Cezati, Maria Caroline de Souza Marques. -Hospital Regional de Barbacena, Barbacena, MG. LPI: Paulo Roberto Rezende. Hospital Regional de Barbacena, Barbacena, MG. LPI: Paulo Roberto Rezende. -Hospital Regional De Cáceres Dr. Antônio Fontes, Cáceres, MT. LPI: Thayla de Arruda Moura, Dennislaine Alves Lima Dantas. Hospital Regional De Cáceres Dr. Antônio Fontes, Cáceres, MT. LPI: Thayla de Arruda Moura, Dennislaine Alves Lima Dantas. -Hospital Regional Justino Luz, Picos, PI. LPI: Raimundo de Carvalho Reis Neto. Hospital Regional Justino Luz, Picos, PI. LPI: Raimundo de Carvalho Reis Neto. -Hospital Região Leste (Paranoá), Brasília, DF. LPI: Sidney Sotero. Hospital Região Leste (Paranoá), Brasília, DF. LPI: Sidney Sotero. -Hospital São Lucas, Garça, SP. LPI: Barbara Cristine Teixeira Ferreira. Hospital São Lucas, Garça, SP. LPI: Barbara Cristine Teixeira Ferreira. -Hospital Tramandaí, Tramandaí, RS. LPI: Jocelaine Lencina, Juliana da Silva Silveira. Hospital Tramandaí, Tramandaí, RS. LPI: Jocelaine Lencina, Juliana da Silva Silveira. -Irmandade da Santa Casa de Misericórdia de Mococa, Mococa, SP. LPI: Luiz Otavio da Silva, Camila Gabriel Carraro. Irmandade da Santa Casa de Misericórdia de Mococa, Mococa, SP. LPI: Luiz Otavio da Silva, Camila Gabriel Carraro. -Santa Casa de Paranavaí, Paranavaí, PR. LPI: Bruno Cesar Pereira Leal. Santa Casa de Paranavaí, Paranavaí, PR. LPI: Bruno Cesar Pereira Leal. Supplementary data The following are the Supplementary data to this article: Multimedia component 1 Multimedia component 2 References Associated Data Supplementary Materials Multimedia component 1 Multimedia component 2